医药生物行业周报 药辅行业迈入成熟期，关注医药辅料优 势企业 2026 年 03 月 02 日 【行情回顾】 【本周观点】 【风险提示】 医药行业政策风险；研发进展不及预期风险；业绩不及预期风险 挖掘价值 投资成长 强于大市（维持） 东方财富证券研究所 证券分析师：何玮 证书编号：S1160517110001 证券分析师：崔晓倩 证书编号：S1160525080001 相对指数表现 -10% -2% 6% 14% 22% 30% 2025/3 2025/9 2026/3 医药生物 沪深300 相关研究 《"小而美"药辅行业迎来产业升级》 2026.02.24 《ADC 商业化进程提速，本土创新药企多 路径布局产能》 2026.02.09 《《药品管理法实施条例》全面修订，推动 医药产业创新与监管升级》 2026.02.03 《医药零售高质量发展政策发布，行业有 望加速整合利好龙头》 2026.01.27 《J.P. Morgan 健康大会召开，中国创新药 企扬帆出海》 2026.01.20 行 业 研 究 / 医 药 生 物 / 证 券 研 究 报 告 本周(2026/02/23-2026/02/27，下同） ...

今日（2.25），港股创新药板块再度飘红，创新药纯度100%的港股通创新药ETF(159570)涨0.56%，盘中成交额快速突破7亿元！资金面上，近10日累计"吸 金"超3.6亿元！最新规模超250亿元，同类规模遥遥领先！ | 5分 15分 30分 60分 日 周 月 更多 | 综合屏 F9 前复权 超级叠加 画线 工具 ♡ ② > | 港股通创新药ETF | | 159570 | | --- | --- | --- | --- | --- | | 剂新药ETF] 2026/02/25 收1.611 幅0.56%(0.009) 开1.605 高1.620 低1.597 均1.607 量367万 换2.36% 振1.44%型 | | | | | | 1.617↑ MA20 1.620Į MA60 1.662Į MA120 1.764Į MA250 1.588↑ | 2025/11/12-2026/02/25(68日)▼ ■ | 1.611 | | +0.009 +0.56% | | | | | SZSE CNY 11:30:00 休市 T+0 融 ▲ Q 中 | | | | 1.900 | 净值走势 | 汇添富 ...

【国泰海通医药】春节期间创新药领域重点新闻梳理-上市公司 恒瑞医药： 1）2/12 CDE官网显示公司递交了ANGPTL3单抗SHR-1918针对HOFH的上市申请。 目前公司暂未披露1918的III期临床结果； 1）2/20 公司公告阿美替尼已获欧洲药品管理局EMA批准在欧盟上市，用于EGFR19del或L858RNSCLC一线治疗， 以及T790MNSCLC治疗； 石药集团： 1）2/16 公司公告旗下受体偏向性GLP1/GIP激动剂月制剂SYH2082在美国获批临床； 信立泰： 翰森制药： 1）2/20 公司公告阿美替尼已获欧洲药品管理局EMA批准在欧盟上市，用于EGFR19del或L858RNSCLC一线治疗， 以及T790MNSCLC治 【国泰海通医药】春节期间创新药领域重点新闻梳理-上市公司 恒瑞医药： 1）2/12 CDE官网显示公司递交了ANGPTL3单抗SHR-1918针对HOFH的上市申请。 目前公司暂未披露1918的III期临床结果； 翰森制药： 1）2/20 公司在《欧洲呼吸杂志子刊-开放研究》ERJ OPEN RESEARCH上披露了IL17RB单抗SM17针对CRSWNP和 IPF ...

证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 FDA 创新药审评政策再松绑，利好创新药板 块 增持（维持） [Table_Tag] [Table_Summary] 投资要点 《降息等多因素支持科研上游持续复 苏，重点推荐皓元医药、奥浦迈等》 2026-02-01 东吴证券研究所 1 / 24 请务必阅读正文之后的免责声明部分 2026 年 02 月 23 日 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 行业走势 -10% -7% -4% -1% 2% 5% 8% 11% 14% 17% 20% 23% 2025/2/24 2025/6/22 2025/10/18 2026/2/13 医药生物 沪深300 相关研究 《分子胶海外风起，国内管线蓄势破 局》 2026-02-09 ◼ 本周（2.9-2.13 号，下同）、年初至今 A 股医药指数涨幅分别为-0.8%、 2.4%，相对沪深 300 的超额收益分别为-1.2%、1.8%；本周、年初至今 恒生生物科技指数涨跌幅分别为 4.8%、12.5%，相对于恒生科技指数跑 赢 7.3%、18.0%；本周 ...

Group 1: Market Overview - The A-share market is experiencing a wide range of fluctuations, with a focus on price-increasing sectors and export industry chains [6][9] - As of February 13, 2026, the major indices showed declines: the Shanghai Composite Index fell by 1.26% to 4082.07 points, and the ChiNext Index dropped by 1.57% to 3275.96 points [6][7] - The overall market sentiment is cautious, with expectations of a gradual return to intrinsic market dynamics as the National People's Congress approaches [6][8] Group 2: Industry Dynamics - Hansoh Pharmaceutical's (3692.HK) Amivantamab has been approved for marketing in the EU for specific types of lung cancer [27] - The world's largest offshore wind farm, Hornsea 3, is set to begin construction, with significant logistical preparations already underway [29] - The CWEA reported that China's wind power installation capacity is expected to grow significantly, with a 49.9% year-on-year increase anticipated for 2025 [31] Group 3: Company Updates - Dongfang Cable (603606.SH) has successfully shipped a large-scale underwater cable to the UK, valued at over 900 million RMB, for use in multiple offshore wind projects [37] - The actual controller of Youkeshu (300209.SZ) plans to increase his stake in the company, reflecting confidence in its business recovery [39] - The electric motorcycle industry is seeing accelerated growth due to new policies and market demand, with over 12.5 million units expected to be replaced under the "old for new" subsidy program in 2025 [33]

Investment Rating - The report maintains a "Buy" rating for the company with a target price adjusted to HKD 42.10 [4][7]. Core Insights - The company's product sales revenue is expected to continue growing rapidly, driven by the successful launch of key innovative drugs in the oncology and liver disease sectors [1][3]. - Increased promotional efforts are anticipated, particularly with the upcoming launch of the drug Amivantamab in the UK, which may lead to higher sales expenses [2]. - Long-term revenue from licensing agreements is expected to increase, particularly from a deal with Glenmark Specialty for the commercialization of Amivantamab in various regions [3]. Financial Summary - Revenue projections for the company are as follows: - 2023: RMB 10,104 million - 2024: RMB 12,261 million (21.3% growth) - 2025E: RMB 15,426 million (25.8% growth) - 2026E: RMB 15,600 million (1.1% growth) - 2027E: RMB 17,644 million (13.1% growth) [6][12] - Shareholder net profit estimates are: - 2023: RMB 3,278 million - 2024: RMB 4,372 million (33.4% growth) - 2025E: RMB 5,434 million (24.3% growth) - 2026E: RMB 4,739 million (-12.8% decline) - 2027E: RMB 5,828 million (23.0% growth) [6][12]. - The company’s earnings per share (EPS) are projected to be: - 2023: RMB 0.55 - 2024: RMB 0.74 - 2025E: RMB 0.92 - 2026E: RMB 0.79 - 2027E: RMB 0.98 [6][12]. Target Price and Valuation - The target price has been adjusted to HKD 42.10 based on a discounted cash flow (DCF) model, reflecting the company's growth potential despite an upward revision in sales expense forecasts [4][7].

Investment Rating - The report maintains a "Buy" rating for the company with a target price adjusted to HKD 42.10 [4][7]. Core Insights - The company's product sales revenue is expected to continue growing rapidly, driven by the successful launch of key innovative drugs in the oncology and liver disease sectors [1][3]. - Increased promotional efforts are anticipated, particularly with the upcoming launch of the drug Amivantamab in the UK, which may lead to higher sales expenses [2]. - Long-term revenue from licensing agreements is expected to increase, particularly from a deal with Glenmark Specialty for the commercialization of Amivantamab in various regions [3]. Financial Summary - Revenue projections for the company are as follows: - 2023: RMB 10,104 million - 2024: RMB 12,261 million (growth rate of 21.3%) - 2025E: RMB 15,426 million (growth rate of 25.8%) - 2026E: RMB 15,600 million (growth rate of 1.1%) - 2027E: RMB 17,644 million (growth rate of 13.1%) [6][12] - Shareholder net profit estimates are: - 2023: RMB 3,278 million - 2024: RMB 4,372 million (growth rate of 33.4%) - 2025E: RMB 5,434 million (growth rate of 24.3%) - 2026E: RMB 4,739 million (decline of 12.8%) - 2027E: RMB 5,828 million (growth rate of 23.0%) [6][12] - The company’s earnings per share (EPS) projections are: - 2023: RMB 0.55 - 2024: RMB 0.74 - 2025E: RMB 0.92 - 2026E: RMB 0.79 - 2027E: RMB 0.98 [6][12] Target Price and Valuation - The target price has been adjusted to HKD 42.10 based on a discounted cash flow (DCF) model, reflecting a potential upside from the current price of HKD 36.62 [4][7].

Group 1: Technology and AI - Alphabet (GOOGL US) is expected to maintain good visibility in its advertising business due to the gradual release of its valuation under pressure from AI search, with a projected cloud business growth rate of over 30% for the year [1] - Alibaba (BABA US) is anticipated to see a cloud business growth rate of 28%-30%, driven by strong demand in China, with significant contributions from its instant retail segment [1] - NVIDIA (NVDA US) is projected to achieve revenue exceeding 500 billion, with strong growth expected from its GB300 product line, which constitutes two-thirds of the Blackwell series [1] Group 2: E-commerce and Internet Services - Tencent (700 HK) is recommended as a top pick due to its strong investment in AI and steady growth in its core gaming and advertising businesses, with a target price of 700 [1] - Tencent Music (TME US) is expected to maintain a stable growth trajectory with a focus on subscription and non-subscription revenue streams, despite some margin pressure from new business initiatives [1] - Kuaishou (1024 HK) is projected to see significant revenue growth driven by its AI-enhanced content ecosystem, with a target price of 93 [2] Group 3: Healthcare and Pharmaceuticals - New Oxygen (SY US) is positioned well in the light medical beauty sector, with plans to expand its self-operated stores significantly by 2025, supported by a strong marketing capability and low customer acquisition costs [2] - Hansoh Pharmaceutical (3692 HK) is focusing on expanding its pipeline in oncology and other major indications, with a strong emphasis on innovative drug development [3] - BeiGene (6160 HK) is expected to exceed management's revenue guidance for 2025, driven by strong sales of its BTK inhibitor, with a projected peak sales potential of over 8 billion [4] Group 4: Energy and Materials - Saudi Aramco (ARAMCO AB) is positioned as a central player in global energy supply, with ongoing investments in hydrogen and carbon capture technologies, enhancing its long-term growth prospects [6] - MP Materials (MP US) is the only company in the U.S. with a fully scaled rare earth supply chain, benefiting from strong demand in the defense and renewable energy sectors [6] - Howmet Aerospace (HWM US) is expected to maintain a strong market position in gas turbine components, with a long order backlog supporting stable revenue growth [5]

Core Insights - The conference titled "New Ecosystem of Three Medical Linkages" was held to discuss clinical innovation and technology empowerment in healthcare, supported by Jiangsu Haosen Pharmaceutical and organized by the China Medical Education Association [1] - The third-generation EGFR-TKI drug, Amivantamab, has been officially included in the new national medical insurance directory for postoperative adjuvant therapy of EGFR mutation-positive non-small cell lung cancer (NSCLC), marking a significant advancement in accessibility for patients [1] Group 1 - The conference emphasized the importance of "Three Medical Linkages" as a core approach to deepen healthcare reform and promote the Healthy China initiative, with experts advocating for collaborative efforts to maximize policy benefits and innovation outcomes [2] - Experts discussed the strategic layout of the national policy encouraging pharmaceutical innovation, optimizing drug review and approval processes, and improving medical insurance payment mechanisms, providing clear policy expectations for the development and application of innovative drugs [2] - The conference highlighted the challenges of lung cancer, which has the highest incidence and mortality rates among malignant tumors in China, with approximately 85% of cases being NSCLC and about 30% of patients diagnosed at an operable early stage facing postoperative recurrence risks [2] Group 2 - The rapid development of Chinese-origin third-generation EGFR-TKI drugs, represented by Amivantamab, offers new options for postoperative adjuvant therapy in early-stage NSCLC, with evidence from the ART study supporting its efficacy for patients in stages II to IIIB [3] - The inclusion of Amivantamab in the national medical insurance directory significantly enhances its affordability, reducing treatment disparities among patients from different regions and economic backgrounds, and facilitating the distribution of quality targeted therapy resources to grassroots medical institutions [3]

Core Insights - A significant breakthrough in treating advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations and MET amplification has been achieved through a "dual-target" therapy combining Savolitinib and Osimertinib, offering new treatment options for patients facing resistance to targeted therapies [3][5]. Group 1: Research Findings - In China, 40%-50% of lung adenocarcinoma patients exhibit EGFR gene mutations, with MET amplification being a major cause of resistance to EGFR-targeted therapies [2][3]. - The study led by Professor Lu Shun involved 211 patients who were randomly assigned to receive either the combination therapy or standard chemotherapy, revealing a median progression-free survival of 8.2 months for the combination group compared to 4.5 months for the chemotherapy group [4]. - The risk of disease recurrence or death was reduced by 66% in the combination therapy group, with 58% of patients achieving objective response compared to 34% in the chemotherapy group [4]. Group 2: Regulatory and Clinical Impact - The combination therapy of Savolitinib and Osimertinib has received approval from the National Medical Products Administration of China for treating EGFR mutation-positive patients with advanced or metastatic non-squamous NSCLC after progression on EGFR-TKI therapy [5]. - Professor Lu Shun has led 29 domestic and international studies on lung cancer, including 17 national Class 1 new drug studies, contributing to the approval and inclusion of several innovative drugs in medical insurance [6].